ライフサイエンスコーパス: balloon-expandable

1 Overall 898 chimney grafts (49.2% balloon expandable, 39.6% self-expanding covered stents,

2 31 consecutive patients undergoing TAVR with balloon-expandable (58%) or self-expandable (42%) valves

3 anscatheter aortic valve implantation with a balloon-expandable (64%) or self-expandable (36%) valve.

4 4 mm in diameter were treated with the new, balloon-expandable ACS MultiLink stent.

5 tive patients underwent MDCT pre-TAVR with a balloon expandable aortic valve.

6 .6% self-expanding covered stents, and 11.2% balloon expandable bare metal stents) were placed in 692

7 Between 1990 and 2004, deployment of balloon-expandable bare stents was attempted in 242 obst

8 and the predictors of such a complication in balloon-expandable (BE) and self-expandable (SE) TAVR re

9 d 1521 underwent TF-TAVR with Edwards SAPIEN balloon-expandable bioprostheses.

10 ortic stenosis to either SAVR or TAVR with a balloon-expandable bovine pericardial tissue valve by ei

11 ranscatheter aortic-valve replacement with a balloon-expandable bovine pericardial valve (either a tr

12 transfemoral transcatheter implantation of a balloon-expandable bovine pericardial valve.

13 Balloon, expandable, cobalt-chrome covered stent (Jotec,

14 The balloon-expandable coil stent has been proved effective

15 Patients who receive the coronary balloon-expandable coil stent with optimal angiographic

16 ber 1994 and May 1995, 369 patients received balloon-expandable coil stents in native coronary arteri

17 the use of local anesthesia, implantation of balloon expandable device, avoidance of urinary catheter

18 nvestigated the efficacy and safety of using balloon expandable drug-eluting stents (DES) to prevent

19 oston Scientific Lotus valve (Lotus) and the balloon-expandable Edwards Sapien 3 (ES3) valve.

20 ore: 9.8 +/- 6.4%) who underwent TAVI with a balloon-expandable Edwards valve (transfemoral: 48%, tra

21 Restenosis within balloon-expandable endovascular stents may occur as a re

22 Balloon-expandable endovascular stents provide a luminal

23 The balloon-expandable ES prosthesis caused significantly mo

24 emoral and the transapical approach with the balloon-expandable ES stent valve, transfemoral TAVI wit

25 follow-up were observed in 4 patients in the balloon-expandable group (3.4% vs. 0%; p = 0.12); all we

26 ed by percutaneous delivery of a 15-mm-long, balloon-expandable metallic stent was performed in 64 ra

27 atients who underwent TAVI with the use of a balloon-expandable (n=22) or self-expandable (n=10) sten

28 rmed in 20 patients undergoing VIV TAVR with balloon-expandable (n=8) or self-expanding (n=12) transc

29 Transfemoral TAVR with a balloon-expandable or self-expandable device.

30 heter deployment of valves requires either a balloon-expandable or self-expandable system.

31 al valves to facilitate VIV TAVR with either balloon-expandable or self-expanding transcatheter valve

32 y assigned 1:1 to either SAVR or TAVR with a balloon expandable pericardial tissue valve.

33 risk of aortic root rupture during TAVR with balloon-expandable prostheses.

34 358 patients underwent transapical TAVI with balloon-expandable prostheses.

35 ocedural strategy of transapical TAVI with a balloon-expandable prosthesis was associated with a low

36 The new balloon-expandable Sapien 3 transcatheter heart valve (S

37 dy investigated the efficacy and safety of a balloon expandable, sirolimus-eluting stent (SES) in pat

38 The Multi-Link stent is a balloon-expandable stainless steel stent with an interco

39 ocalized drug delivery was accomplished with balloon-expandable stainless steel stents coated with a

40 The balloon-expandable, stainless steel, hourglass-shaped, c

41 ation], SIRIUS [SIRolImUS-coated Bx Velocity balloon expandable stent in the treatment of patients wi

42 raphy) from the Sirolimus-coated Bx Velocity Balloon Expandable Stent in the Treatment of Patients wi

43 were performed in 55 lesions treated with a balloon-expandable stent (ACS MultiLink) using standard

44 ry stenoses, who underwent implantation of a balloon-expandable stent after unsuccessful percutaneous

45 ng stent group (n = 32) or the Palmaz-Schatz balloon-expandable stent group (n = 30).

46 Balloon-expandable stent implantation in the SVGs of hig

47 particular, the implications of deploying a balloon-expandable stent in a compressible site are not

48 nd vascular response to placement of a novel balloon-expandable stent in swine with experimentally in

49 The SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients wi

50 81420; Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native

51 ypotension developed in 33.9% of cases after balloon-expandable stent placement versus in 13.6% of ca

52 efit of heparin coating with the BX VELOCITY Balloon-Expandable Stent with HEPACOAT, Carmeda end-poin

53 TIPS (eight with flexible PTFE-encapsulated balloon-expandable stent-grafts and four control TIPS wi

54 tion of stents in the treatment of IAs, from balloon expandable stents, to self-expanding stents, to

55 Short balloon-expandable stents (mean diameter, 14.6 mm +/- 1.

56 Balloon-expandable stents anchored the ends of the graft

57 Balloon-expandable stents are being used increasingly in

58 Balloon-expandable stents covered with polytetrafluoroet

59 Balloon-expandable stents have been used in pulmonary ar

60 Endovascular treatment with balloon-expandable stents is effective, safe, and appare

61 l, Palmaz (Cordis Corp., Warren, New Jersey) balloon-expandable stents provide a safe and durable rev

62 Balloon-expandable stents were placed in 100 consecutive

63 have significant implications for the use of balloon-expandable stents within vascular sites subject

64 leading to larger follow-up lumens than with balloon-expandable stents.

65 sinus stimulation is frequent after CAS with balloon-expandable stents.

66 th patients were treated percutaneously with balloon-expandable stents.

67 SFAs) and hemodialysis conduits treated with balloon-expandable stents.

68 (TAVR) have been based primarily on a single balloon-expandable system.

69 Contained rupture of the aortic root in balloon-expandable TAVI is associated with severe prosth

70 rtic valve area 0.69+/-0.19 cm(2)) underwent balloon-expandable TAVI using the EdwardsSAPIEN Transcat

71 and the frequency of this complication after balloon-expandable TAVI.

72 evaluate the safety and efficacy of PD after balloon expandable TAVR.

73 ify predictors of aortic root rupture during balloon-expandable TAVR by using multidetector computed

74 omatic aortic stenosis and were treated with balloon-expandable TAVR in a single center.

75 in patients with greater than mild PVR after balloon-expandable TAVR.

76 atheter heart valve type (self-expanding vs. balloon-expandable) that fits the given anatomy best.

77 Intentionally underexpanding balloon-expandable THV by underfilling the deployment ba

78 lve implantation using the newest generation balloon-expandable THV is associated with a low risk of

79 The use of the new generation S3 balloon-expandable THV reduced the risk of more than mil

80 Recommendations for balloon-expandable THV size selection were based on an M

81 n MSCT-based TAV sizing was performed (16.7% balloon-expandable THV vs. 17.6% self-expandable THV, p

82 on (AR) grade >/= 2 occurred in 28.4% (19.6% balloon-expandable THV vs. 32.2% self-expandable THV, p

83 sizing was used in 63.5% of patients (77.1% balloon-expandable THV vs. 56.0% self-expandable THV, p

84 11 and December 2014, 167 patients underwent balloon-expandable transcatheter aortic valve implantati

85 e of contained rupture of the aortic root in balloon-expandable transcatheter aortic valve implantati

86 DCT and 3D-TEE for annulus assessment before balloon-expandable transcatheter aortic valve replacemen

87 Aortic root rupture is a major concern with balloon-expandable transcatheter aortic valve replacemen

88 eart valve (Symetis ACURATE neo, n=129) or a balloon-expandable transcatheter heart valve (Edwards SA

89 f 139 patients underwent TAV-in-BAV with the balloon-expandable transcatheter heart valve (THV) (n =

90 The use of a balloon-expandable transcatheter heart valve previously

91 f PVR following TAVR with a third-generation balloon-expandable transcatheter heart valve.

92 associated with a strategy of underexpanding balloon-expandable transcatheter heart valves (THV) when

93 rmine the midterm hemodynamic performance of balloon-expandable transcatheter heart valves.

94 r postprocedural gradients in both self- and balloon-expandable transcatheter valves.

95 patients were randomly assigned to receive a balloon-expandable valve (Edwards Sapien XT) and 120 wer

96 rtery bypass graft (p = 0.043), the use of a balloon-expandable valve (p = 0.023), and previous surgi

97 transient or absent) LBBB after TAVI with a balloon-expandable valve and its clinical consequences a

98 permanent pacemaker was less frequent in the balloon-expandable valve group (17.3% vs 37.6%, P = .001

99 end point occurred in 18.2% of those in the balloon-expandable valve group and 23.1% of the self-exp

100 ascular mortality at 30 days was 4.1% in the balloon-expandable valve group and 4.3% in the self-expa

101 curred in 116 of 121 patients (95.9%) in the balloon-expandable valve group and 93 of 120 patients (7

102 than 1 valve (0.8% vs 5.8%, P = .03) in the balloon-expandable valve group.

103 ortic stenosis undergoing TAVR, the use of a balloon-expandable valve resulted in a greater rate of d

104 ar outcomes following successful TAVI with a balloon-expandable valve were evaluated in 88 patients.

105 implantation (PPI) who underwent TAVI with a balloon-expandable valve were included.

106 Transseptal access and the balloon-expandable valve were used in 33.1% and 89.9%, r

107 pite the higher device success rate with the balloon-expandable valve, 1-year follow-up of patients i

108 ces developed new LBBB following TAVI with a balloon-expandable valve, although it was transient in m

109 frequently in women, in patients receiving a balloon-expandable valve, and in those with a previous s

110 rial fibrillation (AF) underwent TAVI with a balloon-expandable valve.

111 eter aortic valve implantation (TAVI) with a balloon-expandable valve.

112 TVIV was accomplished in all patients using balloon expandable valves (Edwards Lifesciences, Irvine,

113 Since the introduction of the first balloon-expandable valves for stenotic lesions with impl

114 Balloon-expandable valves were used in 97% of cases, wit

115 Valve type (balloon-expandable vs. self-expandable, p = 0.26) and ap